Geneva Capital Management LLC trimmed its position in shares of Globus Medical, Inc. (NYSE:GMED – Free Report) by 11.8% during the 3rd quarter, HoldingsChannel.com reports. The firm owned 1,249,396 shares of the medical device company’s stock after selling 167,671 shares during the period. Globus Medical makes up about 2.6% of Geneva Capital Management LLC’s holdings, making the stock its 11th biggest holding. Geneva Capital Management LLC’s holdings in Globus Medical were worth $93,580,000 as of its most recent filing with the SEC.
Several other institutional investors also recently bought and sold shares of the company. Phoenix Financial Ltd. increased its stake in Globus Medical by 131.8% during the 3rd quarter. Phoenix Financial Ltd. now owns 9,967 shares of the medical device company’s stock valued at $749,000 after purchasing an additional 5,667 shares in the last quarter. William Blair Investment Management LLC raised its holdings in Globus Medical by 12.6% in the third quarter. William Blair Investment Management LLC now owns 1,447,365 shares of the medical device company’s stock worth $108,408,000 after buying an additional 162,469 shares during the last quarter. Allworth Financial LP lifted its stake in shares of Globus Medical by 3.5% in the third quarter. Allworth Financial LP now owns 12,797 shares of the medical device company’s stock worth $1,011,000 after buying an additional 436 shares in the last quarter. Russell Investments Group Ltd. lifted its stake in shares of Globus Medical by 335.0% in the third quarter. Russell Investments Group Ltd. now owns 143,614 shares of the medical device company’s stock worth $10,758,000 after buying an additional 110,602 shares in the last quarter. Finally, Maryland State Retirement & Pension System lifted its stake in shares of Globus Medical by 14.7% in the third quarter. Maryland State Retirement & Pension System now owns 6,743 shares of the medical device company’s stock worth $505,000 after buying an additional 863 shares in the last quarter. 95.16% of the stock is owned by hedge funds and other institutional investors.
Globus Medical Stock Performance
NYSE GMED opened at $72.02 on Monday. Globus Medical, Inc. has a one year low of $70.39 and a one year high of $101.40. The stock has a 50-day moving average of $76.56 and a 200 day moving average of $82.71. The company has a market capitalization of $9.54 billion, a price-to-earnings ratio of 17.69, a PEG ratio of 1.12 and a beta of 0.98.
Globus Medical (NYSE:GMED – Get Free Report) last issued its earnings results on Thursday, November 5th. The medical device company reported $1.23 earnings per share for the quarter, topping analysts’ consensus estimates of $1.20 by $0.03. The business had revenue of $763.72 million during the quarter, compared to analyst estimates of $792.39 million. Globus Medical had a return on equity of 14.43% and a net margin of 17.76%. Globus Medical’s revenue was down .7% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.18 EPS. Globus Medical has set its FY 2026 guidance at 4.950-5.050 EPS. On average, equities analysts predict that Globus Medical, Inc. will post 4.98 earnings per share for the current fiscal year.
Insider Activity
In other news, Director Ann D. Rhoads sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $85.00, for a total transaction of $425,000.00. Following the completion of the transaction, the director directly owned 35,384 shares of the company’s stock, valued at $3,007,640. The trade was a 12.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Stephen T. Zarrilli sold 25,000 shares of the stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $87.04, for a total transaction of $2,176,000.00. Following the transaction, the director owned 25,000 shares in the company, valued at approximately $2,176,000. This trade represents a 50.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 101,666 shares of company stock valued at $7,970,017 in the last 90 days. 18.38% of the stock is currently owned by insiders.
Wall Street Analyst Weigh In
GMED has been the topic of a number of recent analyst reports. Canaccord Genuity Group cut their price target on shares of Globus Medical from $115.00 to $105.00 and set a “buy” rating on the stock in a report on Friday, November 6th. Zacks Research lowered shares of Globus Medical from a “strong-buy” rating to a “hold” rating in a report on Monday, November 9th. Royal Bank Of Canada decreased their price objective on shares of Globus Medical from $115.00 to $85.00 and set an “outperform” rating for the company in a report on Thursday, October 1st. Wells Fargo & Company upped their price objective on Globus Medical from $99.00 to $100.00 and gave the company an “overweight” rating in a research report on Friday, November 6th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Globus Medical in a research note on Friday, October 9th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and seven have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $96.08.
View Our Latest Analysis on Globus Medical
About Globus Medical
Globus Medical is a medical device company focused on musculoskeletal care. Its products include implants and instruments used in spine surgery, as well as solutions for orthopedic trauma and other orthopedic procedures. The company also develops surgical technologies, including robotic navigation and imaging systems designed to support planning and guidance during procedures. Its portfolio expanded significantly in 2023 when Globus Medical completed its combination with NuVasive, a provider of spine care products and technologies.
Featured Stories
- Five stocks we like better than Globus Medical
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding GMED? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Globus Medical, Inc. (NYSE:GMED – Free Report).
Receive News & Ratings for Globus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Globus Medical and related companies with MarketBeat.com's FREE daily email newsletter.
